Axinn partner Chad Landmon participated in a four-part video interview with Tony Hagen of The Center for Biosimilars. They discussed California’s “Pay-for-Delay” Law, the FDA's unique offer of assistance to the Patent and Trademark Office in reviewing patent applications, the potential impact of the Build Back Better Act on the biosimilars industry, and the FDA defining interchangeable biosimilars. Click below to access the interviews.

• Episode 1: "California’s 'Pay-for-Delay' Law"
• Episode 2: "The FDA Reaches Out to the U.S. Patent and Trademark Office"
• Episode 3: "The Build Back Better Act and Biosimilars"
• Episode 4: "Defining Interchangeable Biosimilars More Clearly"